BMS presents promising data for NASH drug

24th April 2017 Uncategorised 0

Bristol-Myers Squibb’s investigational liver disease candidate has hit its targets in a mid-stage trial, supporting further research on the drug as a potential treatment for Nonalcoholic Steatohepatitis (NASH).

More: BMS presents promising data for NASH drug
Source: News